GlassScriptPhysician profile
Matthew Robert Dalessandro
NPI 1750512224
$40,749.33
in general payments reported to CMS, 2019-2025
27 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,236 · 2020: $230 · 2021: $270 · 2022: $636 · 2023: $6,272 · 2024: $12K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $37K · Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $36,733.33 |
| Food and Beverage | $643.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $36,764.77 | 2021-2025 | Auryon Laser System 100-120 Vac |
| Penumbra, INC. | $1,430.62 | 2019-2023 | Penumbra System |
| Endologix LLC | $734.88 | 2019-2022 | |
| Cardiovascular Systems INC. | $396.72 | 2019-2023 | Diamondback Peripheral |
| W. L. Gore & Associates, INC. | $392.11 | 2019-2025 | Gore Tag Conformable Thoracic Endoprosthesis, Gore Excluder Aaa Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Boston Scientific Corporation | $252.86 | 2019-2025 | General - Ultrasound |
| Intact Vascular, INC. | $120.00 | 2019 | |
| Abbott Laboratories | $95.18 | 2020-2024 | Diamondback Peripheral, Absolute Pro, Esprit |
| Philips North America LLC | $68.21 | 2019 | |
| Cook Medical LLC | $54.08 | 2023-2024 | Zenith Spiral-Z, Zenith |
| Inari Medical, INC. | $52.00 | 2023-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Organogenesis INC. | $43.82 | 2025 | Via Matrix |
| Silk Road Medical, INC. | $42.76 | 2021-2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Lemaitre Vascular, INC. | $37.92 | 2023-2025 | Restoreflow, Hydro Lemaitre Valvulotome |
| Medtronic Vascular, INC. | $35.11 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.96 | 2022 | |
| Alnylam Pharmaceuticals INC. | $30.14 | 2025 | Amvuttra |
| Recor Medical INC | $24.91 | 2024 | Paradise Renal Denervation System |
| Janssen Pharmaceuticals, INC | $21.00 | 2023 | Xarelto |
| Reflow Medical INC | $20.10 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.46 | 2022 | |
| Kci USA, INC. | $14.20 | 2019 | |
| Cashflow Solutions, LLC | $14.17 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Pfizer INC. | $13.82 | 2021 | |
| Cordis US Corp. | $13.77 | 2024 | S.M.A.R.T. |
| Terumo Medical Corporation | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Dalessandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.